Coloplast Denmark
Coloplast Denmark A/S is the Danish subsidiary of Coloplast A/S, a publicly listed medical device group developing and selling ostomy bags, hydrophilic catheters, advanced wound dressings, and urology products for patients and healthcare professionals across Denmark and global markets.
- Company typePublic
- Founded1954
- HeadquartersHumlebæk, Denmark
- Headcount501–1,000
- GTM typeB2C
- OfferingHardware or Manufacturing
What Coloplast Denmark does
Coloplast Denmark A/S is the Danish operating subsidiary of Coloplast A/S, a publicly listed (Nasdaq Copenhagen: COLO-B) medical device group headquartered in Humlebæk, Denmark, and founded in 1954. The company develops and markets products and services for people with ostomy, continence, urological, and wound care needs, serving patient end-users, healthcare professionals (district nurses, wound care specialists), and Danish municipalities that authorize product coverage under the Serviceloven §112 Fritvalgsordningen (Free Choice Scheme).
The product portfolio spans four segments: ostomy care (SenSura Mio 1-piece and 2-piece systems, including the SenSura Mio Black line), continence care (SpeediCath hydrophilic-coated catheters, Luja with Micro-hole Zone Technology, SpeediCath Navi with flexible ball tip, Peristeen transanal irrigation, Conveen uridoms), wound care (Biatain silicone/foam/ag dressings, Comfeel Plus, alginate dressings, and the acquired Kerecis fish-skin biologic platform), and interventional urology. Key proprietary technologies include the uniform hydrophilic catheter coating enabling ready-to-use sterile catheterization, micro-hole zone geometry designed to reduce urinary tract infections and achieve complete bladder emptying, and intact fish-skin grafts validated by the Odinn randomized controlled trial (44% wound healing at 16 weeks vs 26.4% standard of care).
Coloplast makes money primarily through medical device product sales, with a recurring subscription-like model driven by chronic patient consumption. Products are paid for either directly by patients via credit card or MobilePay, or by Danish municipalities under the Fritvalgsordningen with home delivery via GLS. Group-level revenue is approximately $4.13 billion USD, with FY 2025/26 guidance of 5-6% organic growth and approximately 5% EBIT growth at constant exchange rates (lowered from ~7% due to Kerecis challenges). The Danish entity operates with a sales-led motion combining healthcare professional recommendation networks, a direct-to-consumer webshop, and municipal reimbursement integration.
Coloplast Denmark firmographics
Firmographics- Name
- Coloplast Denmark
- Legal name
- Coloplast Danmark A/S
- Website
- https://coloplast.dk
- Company type
- Public
- Founded year
- 1954
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Coloplast Denmark A/S is the Danish subsidiary of Coloplast A/S, a publicly listed medical device group developing and selling ostomy bags, hydrophilic catheters, advanced wound dressings, and urology products for patients and healthcare professionals across Denmark and global markets.
- Ownership category
- akta.pro rank
Coloplast Denmark industry classification
Industry- Product category
- Ostomy and Continence Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ostomy Care Products (Pouches, Barriers/Wafers, Accessories, Skin Protection) (HLAHALAG)
- akta.pro secondary industries
- Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies) (HSABAKAH), Medical Supplies & Consumables Wholesale (Non-Device) (CRAOAHAE)
Keywords
Where Coloplast Denmark is headquartered
LocationHeadquarters
- HQ city
- Humlebæk
- HQ country
- Denmark
- HQ region
- Europe
Offices1 record
Markets served
Coloplast Denmark business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Medical device product sales: Coloplast generates revenue through the sale of medical devices including ostomy products, continence products (catheters), wound care products, and urology products. Products are sold to end-users (patients) directly or through municipal/insurance coverage systems, as well as through healthcare institutions.
- Government/insurance reimbursed products: Products are partially or fully reimbursed through Danish municipal coverage (Sundhedsloven §112) for qualifying patients. Customers with prescriptions/authorizations receive products with municipal payment, creating a recurring revenue stream based on patient need.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | Products covered by municipal authorization (Fritvalgsordningen) |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
Coloplast Denmark product offering
Product offeringCore offering
Coloplast Denmark develops, manufactures, and markets medical devices for ostomy care, continence care, wound care, and interventional urology. Core products include hydrophilic-coated intermittent catheters (SpeediCath, Luja), ostomy bags and barriers (SenSura Mio), advanced wound dressings (Biatain), uridoms (Conveen), and transanal irrigation systems (Peristeen). Products are sold to patients directly through a webshop, via municipal reimbursement under the Danish Fritvalgsordningen (Free Choice Scheme), and through healthcare professional recommendations.
Differentiator
Problem solved
Functional benefit
Brands
- SenSura Mio: Ostomy bag product line including 1-piece and 2-piece systems
- SpeediCath
- Biatain
- Conveen
- Luja
- Peristeen
- Fritvalgsordningen Coloplast
Products and services
- SenSura Mio Ostomy Bags One-piece and two-piece ostomy bags and barriers for people with colostomy, ileostomy, or urostomy. Designed to manage stoma output discreetly, prevent leakage, and protect peristomal skin. Available in standard and black variants with Click and Flex coupling systems.
- SpeediCath Hydrophilic Catheters
Quantifiable outcome
- Complete bladder emptying defined as <10ml residual
- +2 more outcomes
Companies that use Coloplast Denmark
Customer profileNamed customers2 records
Segments5 records
Ideal customer profiles3 records
Coloplast Denmark technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature5 records
Coloplast Denmark partnerships and signals
Strategic signalScale indicators8 records
Recent moves6 records
Expansion highlights6 records
Coloplast Denmark competitors and assessment
Company assessmentBroad incumbents
- Smith+Nephew: Global medical devices incumbent with material advanced wound care franchise (Allevyn, PICO) competing with Coloplast's Biatain portfolio and Kerecis biologic platform.
- Mölnlycke Health Care: Larger wound care and surgical solutions player owning Wellspect; competes with Coloplast's Biatain advanced wound dressings and indirectly through its catheter subsidiary in Coloplast's core franchises.
- Boston Scientific: Major medical device incumbent with a urology franchise (interventional stone management, pelvic health) that overlaps with Coloplast's interventional urology segment, particularly for surgical meshes and erectile dysfunction treatment.
- Medtronic: Diversified medical device leader with a urology and pelvic health franchise that intersects with Coloplast's interventional urology segment, although Medtronic operates across a much broader device portfolio.
- B. Braun: Large diversified medical device and infusion solutions company with an Actreen catheter line competing in intermittent self-catheterization and broader urology supplies overlapping with Coloplast's SpeediCath.
- 3M Health Care: Broad incumbent in wound care and skin health (3M Tegaderm, V.A.C. therapy) that competes with Coloplast's Biatain advanced wound dressings across hospital and home care settings.
Direct peers
- Hollister Incorporated: Direct competitor in ostomy care and continence care, and one of the three global leaders in ostomy dressings alongside Coloplast and ConvaTec. Privately held with overlapping product portfolios across stoma and continence.
- Wellspect Healthcare: Direct competitor in intermittent catheters (LoFric) and bowel irrigation (Navina), competing head-to-head with Coloplast's SpeediCath and Peristeen franchises. Owned by Mölnlycke Health Care.
- ConvaTec: Direct global competitor in ostomy care, continence care, and advanced wound care. ConvaTec is one of the three market leaders in ostomy dressings alongside Coloplast and Hollister, with overlapping hospital and home distribution channels.
Emerging players
- Atos Medical: Wholly-owned Coloplast subsidiary acquired from PAI Partners for EUR 2,155M; included as a peer reference because the laryngectomy franchise is a distinct intimate-healthcare vertical that benchmarks against other voice prosthesis players such as InHealth Technologies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Coloplast Denmark social profiles
Digital presenceColoplast Denmark financial estimates
Financial estimateRevenue estimate
Valuation estimate
Coloplast Denmark leadership team
Management profileNumber of profiles
Profiles5 records
Coloplast Denmark subsidiaries and ownership
Company hierarchySubsidiaries2 records
Coloplast Denmark funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Coloplast Denmark M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Coloplast Denmark
What does Coloplast Denmark do?
Coloplast Denmark develops, manufactures, and markets medical devices for ostomy care, continence care, wound care, and interventional urology. Core products include hydrophilic-coated intermittent catheters (SpeediCath, Luja), ostomy bags and barriers (SenSura Mio), advanced wound dressings (Biatain), uridoms (Conveen), and transanal irrigation systems (Peristeen). Products are sold to patients directly through a webshop, via municipal reimbursement under the Danish Fritvalgsordningen (Free Choice Scheme), and through healthcare professional recommendations.
Is Coloplast Denmark a public or private company?
Coloplast Denmark is a public company. It is classified as public and is currently operating.
When was Coloplast Denmark founded?
Coloplast Denmark was founded in 1954. It employs 501 to 1,000 people.
Where is Coloplast Denmark based?
Coloplast Denmark is headquartered in Humlebæk, Denmark, in the Europe region.
How does Coloplast Denmark make money?
Two revenue lines are on record. Medical device product sales are the primary driver. The others are government/insurance reimbursed products.
Who are Coloplast Denmark's main competitors?
Broad incumbents on record are Smith+Nephew, Mölnlycke Health Care, Boston Scientific, Medtronic, B. Braun and 3M Health Care. Direct peers are Hollister Incorporated, Wellspect Healthcare and ConvaTec. Atos Medical is listed as an emerging player.
Does Coloplast Denmark have an API?
No public API is recorded for Coloplast Denmark.
What industry is Coloplast Denmark in?
Coloplast Denmark's product category is Ostomy and Continence Medical Devices. Its primary akta.pro industry code is HLAHALAG, Ostomy Care Products (Pouches, Barriers/Wafers, Accessories, Skin Protection), with a secondary code of HSABAKAH, Incontinence & Urological Supplies (Catheters, Briefs, Ostomy Supplies). Its NAICS code is 339113 and its SIC code is 5047.